Table 2 The INF-γ secretion function of lymphocytes in healthy control group versus CRC group as well as early-stage group versus advanced-stage group.
From: Characteristics of circulating adaptive immune cells in patients with colorectal cancer
Variables | Healthy control group versus CRC group | Early-stage group versus advanced-stage group | ||||
|---|---|---|---|---|---|---|
Healthy control group (n = 28) | CRC group (n = 20) | P-value | Early-stage group (n = 7) | Advanced-stage group (n = 13) | P-value | |
Age (years) | 59.5 (58.5–70) | 65 (58.5–70) | 0.571 | 66 (47–71) | 65 (59–68) | 1.000 |
Sex (Male/Female) | 13 (46.4%)/15 (53.6%) | 14 (70%)/6 (30%) | 0.105 | 4 (57.1%)/3 (42.9%) | 10 (76.9%)/3 (23.1%) | 0.357 |
CD3+INF-γ+ cell, % of T cells | 43.4 (33.3–52.8) | 25.8 (18.1–43.7) | 0.004 | 23.5 (19.4–39.2) | 26.5 (15.3–44.9) | 0.905 |
CD4+CD8-INF-γ+ T, % of Th | 21.5 (15.5–28.0) | 13.6 (8.9–18.4) | 0.004 | 12.7 (9.9–18.2) | 14.5 (7.9–18.7) | 0.968 |
CD4-CD8+ INF-γ+ T, % of Tc | 73.0 (67.3–84.1) | 68.5 (44.9–82.7) | 0.149 | 64.8 (62.7–82.6) | 72.3 (43.0–82.9) | 0.501 |
